the aid library

LIST OPTIONS

Filter

7008

Sort by:

Direction:

Download (211)

View PDF (1255)

WHO checklist for influenza pandemic preparedness planning

World Health Organization (2005) C_WHO

The aim of the pandemic preparedness checklist is primarily to provide an outline of the essential minimum elements of preparedness, as well as elements of preparedness that are considered desirable. It is recommended that responsible authorities or institutes in countries that are in the process of... more

Download (158)

View PDF (304)

Philippines Situation Report 4 - Dengue Outbreak (13 Aug 2019)

World Health Organization WHO (2019) C_WHO

167,607 dengue cases, including 720 deaths, reported from 1 January to 27 July 2019: 97% higher than in 2018, in spite of a delayed rainy season. Case Fatality Rate (CFR) of 0.43% as of 27 July 2019 is lower than in the same time period in 2018 (0.54%), but still significantly higher than the reg... more

Download (510)

View PDF (1455)

Pandemic influenza preparedness Framework for the sharing of influenza viruses and access to vaccines and other benefits

World Health Organization WHO (2022) C_WHO

2nd edition . This Framework applies to the sharing of H5N1 and other influenza viruses with human pandemic potential and the sharing of benefits. This Framework does not apply to seasonal influenza viruses or other non-influenza pathogens or biological substances that may be contained in clinical ... more

Download (268)

View PDF (391)

Risk reduction of cognitive decline and dementia: WHO guideline

World Health Organization WHO (2019) C_WHO

The WHO Guidelines on risk reduction of cognitive decline and dementia provide evidence-based recommendations on lifestyle behaviours and interventions to delay or prevent cognitive decline and dementia. These WHO Guidelines are an important tool for health care providers as well as governments, pol... more

Download (291)

View PDF (570)

WHO Report on Surveillance of Antibiotic Consumption

World Health Organization WHO (2018) C_WHO

2016-2018 Early implementation, This report presents 2015 data on the consumption of systemic antibiotics from 65 countries and areas, contributing to our understanding of how antibiotics are used in these countries. In addition, the report documents early efforts of the World Health Organization (... more

Download (1647)

View PDF (2658)

Guidelines for the screening, care and treatment of persions with hepatitis C infection. Updated Version, April 2016
recommended

World Health Organization WHO (2016) C_WHO

The objectives of these WHO guidelines are to provide updated evidence- based recommendations for the treatment of persons with hepatitis C infection using, where possible, all DAA-only combinations. The guidelines also provide recommendations on the preferred regimens based on a patient’s HCV gen... more

Download (582)

View PDF (993)

WHO Expert Consultation on Rabies. 3rd report

Abela-Ridder, B. World Health Organisation (WHO) (2018) C_WHO

WHO TRS N°1012. Key updates include: (i) surveillance strategies, including cross-sectoral linking of systems and suitable diagnostics; (ii) the latest recommendations on human and animal immunization; (iii) palliative care in lowresource settings; (iv) risk assessment to guide management of bite... more

Download (304)

View PDF (351)

HIV drug resistance report 2021

World Health Organization (WHO) (2021) C_WHO

The HIV drug resistance report 2021 summarizes findings from 38 countries that had finalized the surveys by the time of this report and shared data with WHO. Pretreatment HIVDR to non-nucleoside reverse-transcriptase inhibitors (NNRTI) can affect more than 10% of adults starting therapy and is fo... more

Download (1486)

View PDF (1971)

Measles SIAs Field Guide

World Health Organization; Regional Office for Africa (2006)

The Regional strategy for measles control recommends that a second opportunity for measles immunization be provided to all children irrespective of their vaccination status or history of clinical measles. The preferred method of provision of a second opportunity is through Supplemental Immunization ... more

Download (501)

View PDF (1871)

Guideline ‒ Alternative mass drug administration regimens to eliminate lymphatic filariasis
recommended

World Health Organization WHO (2017) C_WHO

Lymphatic filariasis is a vector-borne neglected tropical disease that causes damage of the lymphatic system and can lead to lymphoedema (elephantiasis) and hydrocele in infected individuals. The global baseline estimate of persons affected by lymphatic filariasis is 25 million men with hydrocele an... more

Download (377)

View PDF (324)

WHO report on cancer: setting priorities, investing wisely and providing care for all

World Health Organization WHO (2020) C1

Ramped-up cancer services could save 7 million lives over the next decade—and addressing huge service gaps between rich and poor countries is key to success, according to this report. In 2019, over 90% of high-income countries reported that comprehensive cancer treatment services were available... more

Download (129)

View PDF (131)

Hospital Readiness Checklist for COVID-19

World Health Organization (Europe) (2020) C_WHO

Interim Version 24, February 2020 This checklist has been prepared with the aim of supporting hospital managers and emergency planners in achieving the above by defining and initiating actions needed to ensure a rapid response to the COVID-19 outbreak. The checklist is structured on eleven key co... more

Download (207)

View PDF (390)

WHO guidelines for the use of thermal ablation for cervical pre-cancer lesions

World Health Organization (2019) C_WHO

It is estimated that more than 311 000 women die of cervical cancer each year. Of these deaths, 91% occur in low- and middle-income countries. Demographic changes and a lack of action mean that the number of deaths per year is projected to reach 460 000 by 2040.

Download (113)

View PDF (156)

A Global Strategy for tuberculosis research and innovation

World Health Organization WHO (2020) C_WHO

The Global Strategy for Tuberculosis Research and Innovation will support the efforts of governments and other stakeholders to accelerate TB research and innovation, and improve equitable access to the benefits of research. Availabl in Arabic, Chinese, English, French, Spanish and Russian

Download (740)

View PDF (302)

WHO labour care guide: user’s manual
recommended

World Health Organization WHO (2020) C_WHO

The WHO Labour Care Guide is a tool that aims to support good-quality, evidence-based, respectful care during labour and childbirth, irrespective of the setting or level of health care. This manual has been developed to help skilled health personnel to successfully use the WHO Labour Care Guide. The... more

Download (190)

View PDF (228)

Monitoring and restricting digital marketing of unhealthy products to children and adolescents

World Health OrganizationEurope (2019) C_WHO

The WHO European Office for the Prevention and Control of Noncommunicable Diseases organized an expert meeting on monitoring of digital marketing of unhealthy products to children and adolescents in June 2018. Based on that meeting, this report aims to provide a tool to support Member States in moni... more

Download (85)

View PDF (1003)

Covid-19 vaccines: safety surveillance manual

World Health Organization WHO (2020) C_WHO

22 December 2020 The COVID-19 vaccine safety guidance manual has been developed upon recommendation and guidance of GACVS members, as well as by experts incorporating current and available information critical to all stakeholders when COVID-19 vaccines will be introduced. For ease of use, the man... more

Download (138)

View PDF (147)

Improving early childhood development: WHO Guideline

World Health Organization WHO (2020) C_WHO

Enabling young children to achieve their full developmental potential is a human right and an essential requisite for sustainable development. Given the critical importance of enabling children to make the best start in life, the health sector, among other sectors, has an important role and responsi... more

Download (85)

View PDF (664)

Antimicrobial Resistance Resource Platform
recommended

World Health Organization WHO (2022) C_WHO

Antimicrobial resistance (AMR) threatens the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses and fungi. AMR occurs when bacteria, viruses, fungi and parasites change over time and no longer respond to medicines making infections ha... more

Download (239)

View PDF (322)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Guidelines for the screening, care and treatment of persions with hepatitis C infection. Updated Version, April 2016 recommended

Guideline ‒ Alternative mass drug administration regimens to eliminate lymphatic filariasis recommended

WHO labour care guide: user’s manual recommended

Antimicrobial Resistance Resource Platform recommended

Guidelines for the screening, care and treatment of persions with hepatitis C infection. Updated Version, April 2016
recommended

Guideline ‒ Alternative mass drug administration regimens to eliminate lymphatic filariasis
recommended

WHO labour care guide: user’s manual
recommended

Antimicrobial Resistance Resource Platform
recommended